蛋白激酶B
生物
磷酸化
癌症研究
原癌基因蛋白质c-akt
细胞生长
转录因子
细胞周期
PI3K/AKT/mTOR通路
细胞生物学
信号转导
分子生物学
细胞
生物化学
基因
作者
Brent W. Sutherland,Jill E. Kucab,Joyce C. Wu,Cathy Lee,Maggie C.U. Cheang,Erika Yorida,Dmitry Turbin,Shoukat Dedhar,Colleen C. Nelson,Michaël Pollak,H. Leighton Grimes,Kathy D. Miller,Sunil Badve,David G. Huntsman,C Blake-Gilks,Min Chen,Catherine J. Pallen,Sandra E. Dunn
出处
期刊:Oncogene
[Springer Nature]
日期:2005-04-04
卷期号:24 (26): 4281-4292
被引量:283
标识
DOI:10.1038/sj.onc.1208590
摘要
Akt/PKB is a serine/threonine kinase that promotes tumor cell growth by phosphorylating transcription factors and cell cycle proteins. There is particular interest in finding tumor-specific substrates for Akt to understand how this protein functions in cancer and to provide new avenues for therapeutic targeting. Our laboratory sought to identify novel Akt substrates that are expressed in breast cancer. In this study, we determined that activated Akt is positively correlated with the protein expression of the transcription/translation factor Y-box binding protein-1 (YB-1) in primary breast cancer by screening tumor tissue microarrays. We therefore questioned whether Akt and YB-1 might be functionally linked. Herein, we illustrate that activated Akt binds to and phosphorylates the YB-1 cold shock domain at Ser102. We then addressed the functional significance of disrupting Ser102 by mutating it to Ala102. Following the stable expression of Flag:YB-1 and Flag:YB-1 (Ala102) in MCF-7 cells, we observed that disruption of the Akt phosphorylation site on YB-1 suppressed tumor cell growth in soft agar and in monolayer. This correlated with an inhibition of nuclear translocation by the YB-1(Ala102) mutant. In conclusion, YB-1 is a new Akt substrate and disruption of this specific site inhibits tumor cell growth.
科研通智能强力驱动
Strongly Powered by AbleSci AI